E
Eric J. Feldman
Researcher at Cornell University
Publications - 199
Citations - 11076
Eric J. Feldman is an academic researcher from Cornell University. The author has contributed to research in topics: Leukemia & Cytarabine. The author has an hindex of 44, co-authored 189 publications receiving 10516 citations. Previous affiliations of Eric J. Feldman include NewYork–Presbyterian Hospital & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd,Krzysztof Mrózek,Richard K. Dodge,Andrew J. Carroll,Colin G. Edwards,Diane C. Arthur,Mark J. Pettenati,Shivanand R. Patil,Kathleen W. Rao,Michael S. Watson,Prasad Koduru,Joseph O. Moore,Richard Stone,Robert J. Mayer,Eric J. Feldman,Frederick R. Davey,Charles A. Schiffer,Richard A. Larson,Clara D. Bloomfield +18 more
TL;DR: In this paper, the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-to-5-year overall survival (OS) of acute myeloid leukemia (AML) patients was investigated.
Journal ArticleDOI
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers,Andreas Hochhaus,Eric J. Feldman,John M. Goldman,Carole B. Miller,Oliver G. Ottmann,Charles A. Schiffer,Moshe Talpaz,François Guilhot,Michael W. Deininger,Thomas M. Fischer,S. O'Brien,Richard Stone,Carlo Gambacorti-Passerini,Nigel H. Russell,Jose J. Reiffers,Thomas C. Shea,Bernard Chapuis,Steven Coutre,Sante Tura,Enrica Morra,Richard A. Larson,Alan Saven,Christian Peschel,Alois Gratwohl,Franco Mandelli,Monique Ben-Am,Insa Gathmann,Renaud Capdeville,Ronald Paquette,Brian J. Druker +30 more
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
Journal ArticleDOI
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F. List,Gordon W. Dewald,John M. Bennett,A. Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard Stone,Craig B. Reeder,Kenton Wride,John Patin,Michele Schmidt,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.
Journal ArticleDOI
Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
Thomas Fischer,Richard Stone,Daniel J. DeAngelo,Ilene Galinsky,Elihu H. Estey,Carlo Lanza,Edward Fox,Gerhard Ehninger,Eric J. Feldman,Gary J. Schiller,Virginia M. Klimek,Stephen D. Nimer,D. Gary Gilliland,Catherine Dutreix,Alice Huntsman-Labed,Jodi Virkus,Francis J. Giles +16 more
TL;DR: The results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type AML, and the degree of clinical activity observed supports additional studies that combine midosturin and other agents such as chemotherapy especially in FLT 3-Mutant AML.
Journal ArticleDOI
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza,James A. Reeves,Eric J. Feldman,Gordon W. Dewald,John M. Bennett,H. Joachim Deeg,Luke Dreisbach,Charles A. Schiffer,Richard Stone,Peter L. Greenberg,Peter T. Curtin,Virginia M. Klimek,Jamile M. Shammo,Deborah A. Thomas,Robert Knight,Michele Schmidt,Kenton Wride,Jerome B. Zeldis,Alan F. List +18 more
TL;DR: Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality.